Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors

The aims of this study were (i) to evaluate the effect of talazoparib (1 mg once daily) on cardiac repolarization in patients with advanced solid tumors by assessing corrected QT interval (QTc) and (ii) to examine the relationship between plasma talazoparib concentration and QTc. In this open-label...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Anticancer Drugs
Main Authors: Hoffman, Justin, Chakrabarti, Jayeta, Plotka, Anna, Milillo Naraine, Adriana, Kanamori, David, Moroose, Rebecca, Nguyen, Linh, Wang, Diane, Wainberg, Zev A.
Format: Artigo
Jezik:Inglês
Izdano: Lippincott Williams & Wilkins 2019
Teme:
Clinical Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6485310/
https://ncbi.nlm.nih.gov/pubmed/30875341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CAD.0000000000000772
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki